Quality of Life Research

, Volume 25, Issue 11, pp 2693–2710

EQ-5D in Central and Eastern Europe: 2000–2015

  • Fanni Rencz
  • László Gulácsi
  • Michael Drummond
  • Dominik Golicki
  • Valentina Prevolnik Rupel
  • Judit Simon
  • Elly A. Stolk
  • Valentin Brodszky
  • Petra Baji
  • Jakub Závada
  • Guenka Petrova
  • Alexandru Rotar
  • Márta Péntek
Review

DOI: 10.1007/s11136-016-1375-6

Cite this article as:
Rencz, F., Gulácsi, L., Drummond, M. et al. Qual Life Res (2016) 25: 2693. doi:10.1007/s11136-016-1375-6

Abstract

Objective

Cost per quality-adjusted life year data are required for reimbursement decisions in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly used instrument to generate utility values in CEE. This study aims to systematically review the literature on EQ-5D from eight CEE countries.

Methods

An electronic database search was performed up to 1 July 2015 to identify original EQ-5D studies from the countries of interest. We analysed the use of EQ-5D with respect to clinical areas, methodological rigor, population norms and value sets.

Results

We identified 143 studies providing 152 country-specific results with a total sample size of 81,619: Austria (n = 11), Bulgaria (n = 6), Czech Republic (n = 18), Hungary (n = 47), Poland (n = 51), Romania (n = 2), Slovakia (n = 3) and Slovenia (n = 14). Cardiovascular (21 %), neurologic (17 %), musculoskeletal (15 %) and endocrine, nutritional and metabolic diseases (13 %) were the most frequently studied clinical areas. Overall, 112 (78 %) of the studies reported EQ VAS results and 86 (60 %) EQ-5D index scores, of which 27 (31 %) did not specify the applied tariff. Hungary, Poland and Slovenia have population norms. Poland and Slovenia also have a national value set.

Conclusions

Increasing use of EQ-5D is observed throughout CEE. The spread of health technology assessment activities in countries seems to be reflected in the number of EQ-5D studies. However, improvement in informed use and methodological quality of reporting is needed. In jurisdictions where no national value set is available, in order to ensure comparability we recommend to apply the most frequently used UK tariff. Regional collaboration between CEE countries should be strengthened.

Keywords

EQ-5D Health-related quality of life Value sets Health technology assessment Cost-effectiveness analysis Central and Eastern Europe 

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Fanni Rencz
    • 1
    • 2
  • László Gulácsi
    • 1
  • Michael Drummond
    • 3
  • Dominik Golicki
    • 4
  • Valentina Prevolnik Rupel
    • 5
  • Judit Simon
    • 6
  • Elly A. Stolk
    • 7
  • Valentin Brodszky
    • 1
  • Petra Baji
    • 1
  • Jakub Závada
    • 8
  • Guenka Petrova
    • 9
  • Alexandru Rotar
    • 10
  • Márta Péntek
    • 1
  1. 1.Department of Health EconomicsCorvinus University of BudapestBudapestHungary
  2. 2.Semmelweis University Doctoral School of Clinical MedicineBudapestHungary
  3. 3.Centre for Health EconomicsUniversity of YorkHeslingtonUK
  4. 4.Department of Experimental and Clinical PharmacologyMedical University of Warsaw, PolandWarsawPoland
  5. 5.Institute for Economic ResearchLjubljanaSlovenia
  6. 6.Department of Health Economics, Centre for Public HealthMedical University of ViennaViennaAustria
  7. 7.Institute of Health Policy and ManagementErasmus University RotterdamRotterdamThe Netherlands
  8. 8.Institute of Rheumatology1st Faculty of Medicine, Charles UniversityPragueCzech Republic
  9. 9.Department of Social Pharmacy and Pharmacoeconomics, Faculty of PharmacyMedical UniversitySofiaBulgaria
  10. 10.Department of Social MedicineUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations